BG105041A - Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating muscaloskeletal frailty - Google Patents

Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating muscaloskeletal frailty

Info

Publication number
BG105041A
BG105041A BG105041A BG10504100A BG105041A BG 105041 A BG105041 A BG 105041A BG 105041 A BG105041 A BG 105041A BG 10504100 A BG10504100 A BG 10504100A BG 105041 A BG105041 A BG 105041A
Authority
BG
Bulgaria
Prior art keywords
frailty
treating
muscaloskeletal
ghs
serm
Prior art date
Application number
BG105041A
Other languages
Bulgarian (bg)
English (en)
Inventor
Hua KE
Mei Li
Lydia PAN
David Thompson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG105041A publication Critical patent/BG105041A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105041A 1998-06-16 2000-12-11 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating muscaloskeletal frailty BG105041A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16
PCT/IB1999/001117 WO1999065486A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
BG105041A true BG105041A (en) 2001-08-31

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105041A BG105041A (en) 1998-06-16 2000-12-11 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating muscaloskeletal frailty

Country Status (30)

Country Link
EP (1) EP1087764A1 (xx)
JP (1) JP2002518326A (xx)
KR (1) KR20010052852A (xx)
CN (1) CN1301160A (xx)
AP (1) AP9901582A0 (xx)
AR (1) AR018869A1 (xx)
AU (1) AU4054799A (xx)
BG (1) BG105041A (xx)
BR (1) BR9911324A (xx)
CA (1) CA2335134A1 (xx)
CO (1) CO5070587A1 (xx)
EA (1) EA200001186A1 (xx)
GT (1) GT199900087A (xx)
HN (1) HN1999000097A (xx)
HR (1) HRP20000859A2 (xx)
HU (1) HUP0102505A3 (xx)
ID (1) ID27599A (xx)
IL (1) IL138630A0 (xx)
IS (1) IS5691A (xx)
MA (1) MA26652A1 (xx)
NO (1) NO20006312L (xx)
OA (1) OA11505A (xx)
PA (1) PA8475901A1 (xx)
PE (1) PE20000646A1 (xx)
PL (1) PL344981A1 (xx)
SK (1) SK18912000A3 (xx)
TN (1) TNSN99124A1 (xx)
TR (1) TR200003544T2 (xx)
WO (1) WO1999065486A1 (xx)
ZA (1) ZA993975B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
ATE346159T1 (de) 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
AR018869A1 (es) 2001-12-12
HUP0102505A2 (hu) 2001-11-28
IL138630A0 (en) 2001-10-31
OA11505A (en) 2004-05-07
NO20006312D0 (no) 2000-12-12
ID27599A (id) 2001-04-12
ZA993975B (en) 2000-12-15
HRP20000859A2 (en) 2001-04-30
HN1999000097A (es) 1999-11-03
AU4054799A (en) 2000-01-05
AP9901582A0 (en) 1999-06-30
TR200003544T2 (tr) 2001-04-20
SK18912000A3 (sk) 2001-10-08
PE20000646A1 (es) 2000-08-05
JP2002518326A (ja) 2002-06-25
HUP0102505A3 (en) 2002-12-28
BR9911324A (pt) 2001-04-03
GT199900087A (es) 2000-12-07
MA26652A1 (fr) 2004-12-20
WO1999065486A1 (en) 1999-12-23
TNSN99124A1 (fr) 2005-11-10
PA8475901A1 (es) 2000-05-24
CO5070587A1 (es) 2001-08-28
KR20010052852A (ko) 2001-06-25
EA200001186A1 (ru) 2001-06-25
PL344981A1 (en) 2001-11-19
NO20006312L (no) 2000-12-12
IS5691A (is) 2000-10-27
CA2335134A1 (en) 1999-12-23
EP1087764A1 (en) 2001-04-04
CN1301160A (zh) 2001-06-27

Similar Documents

Publication Publication Date Title
IL145429A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
BR0009083A (pt) Derivado de amida, processo para a preparação de um derivado de amida, composição farmacêutica, uso de um derivado de amida, método de tratamento de doenças ou de condições médicas mediadas por citocinas
NO990663L (no) Substituerte pyrimidinderivater og deres farmas°ytiske anvendelse
UA66945C2 (uk) ПОХІДНІ ПУРИНУ З ВЛАСТИВОСТЯМИ АГОНІСТА ЛЮДСЬКОГО А2<sub>А</sub> РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
BG105041A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating muscaloskeletal frailty
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra
PL315035A1 (en) Cyclic amide derivatives as antagonistic substances in respect to neurokinin a
IL105801A0 (en) 7-(2-aminoethyl)-benzothiazolones,their preparation and pharmaceutical compositions containing them
BG105125A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
BG105128A (en) Therapeutic combinations of selective estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
GB9109972D0 (en) Therapeutic compounds
GEP20043181B (en) Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators, Composition Containing Them and Their Use for Treatment Progesterone-Related Maladies
MY104129A (en) Treatment of arthritis.
BR9814403A (pt) "derivados do indol úteis para o tratamento, entre outros, de osteoporose"
IL111579A (en) Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating desynchronization disorders
IL108085A0 (en) Serotoninergic ergoline derivatives their preparation and pharmacutical compositions containing them
PT966968E (pt) Combinacoes terapeuticas compreendendo um modulador de receptor de estrogenio selectivo e prostaglandina e2
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
MX2024007713A (es) Formas solidas de un inhibidor de tyk2, metodo de preparacion y uso de estas.
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine